Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

A new study led by Children's Hospital Los Angeles has found a novel mechanism behind neuroblastoma progression: the shape and structure of the extracellular matrix.